Literature DB >> 6224415

T8 chronic lymphocytic leukemia. A distinctive disorder related to T8 lymphocytosis.

J U Brisbane, L D Berman, M E Osband, R S Neiman.   

Abstract

A case of T chronic lymphocytic leukemia (CLL) was first suspected on histologic and cytochemical examination of a splenectomy specimen. Later the patient became frankly leukemic with an E+/T3+/T8+/T4- phenotype. From our case and other reported cases of T-CLL studied with monoclonal antisera, the authors conclude that there are significant clinical and morphologic differences between T4 CLL and T8 CLL. In contrast to T4 CLL, T8 CLL characteristically presents with relatively low lymphocyte counts, little organ involvement, and often only discreet bone marrow involvement, and has a long clinical course. The leukemic cells are often large and have abundant cytoplasm with azurophilic granules. Similar features in cases reported as T8 lymphocytosis with neutropenia lead us to consider both entities part of a spectrum of the same disorder.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6224415     DOI: 10.1093/ajcp/80.3.391

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

1.  Pathology of the spleen in large granular lymphocyte leukaemia.

Authors:  D F Griffiths; B Jasani; G R Standen
Journal:  J Clin Pathol       Date:  1989-08       Impact factor: 3.411

2.  T gamma lymphocytosis is clinically non-progressive but immunologically heterogeneous.

Authors:  F Miedema; F G Terpstra; J W Smit; J P van der Veen; C J Melief
Journal:  Clin Exp Immunol       Date:  1985-08       Impact factor: 4.330

3.  Lymphocyte markers and clinical expression of lymphoproliferative disorders with moderate lymphocytosis.

Authors:  J Economidou; H Choremi; N Konstantinidou; A Kofina; K Psarra; K Stefanoudaki; A Papayannis; F Economopoulos; J Dervenoulas; J Vlachos
Journal:  Br J Cancer       Date:  1986-10       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.